PAPER Stewart-Archer LA, Afghani A, Toye CM, Gomez FA
SEARCH RESULTS
331254 RESULTS
PAPER Vanni N, Fruscione F, Ferlazzo E, Striano P, Robbiano A, Traverso M, Sander T, Falace A, Gazzerro E, Bramanti P, Bielawski J, Fassio A, Minetti C, Genton P, Zara F
Impairment of Ceramide Synthesis Causes a Novel Progressive Myoclonus Epilepsy.
Ann Neurol. 2014 Apr 30; PubMed: 24782409PAPER Iravani MM, Sadeghian M, Rose S, Jenner P
Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.
J Neural Transm. 2014 Apr 30; PubMed: 24781752PAPER Knight EM, Gandy S
Immunomodulation and AD--down but not out.
J Clin Immunol. 2014 Jul;34 Suppl 1:S70-3. Epub 2014 Apr 30 PubMed: 24781637PAPER Harrison C
Neurodegenerative disorders: Blood-based biomarkers for Alzheimer's disease?
Nat Rev Drug Discov. 2014 Apr 30;13(5) PubMed: 24781547PAPER Gromova OA, Torshin II, Gogoleva IV
[Mechanisms of neurotrophic and neuroprotective effects of cerebrolysin in cerebral ischemia.]
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(3 vypusk 2 Insul't):43-50. PubMed: 24781241PAPER Osman EY, Miller MR, Robbins KL, Lombardi AM, Atkinson AK, Brehm AJ, Lorson CL
Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models.
Hum Mol Genet. 2014 Apr 29; PubMed: 24781211Dementia Screening and Detection Meeting
CONFERENCE 2011-11-22 00:00:00-2011-11-22 00:00:00 New York, New York, U.S.A. 22 November 2011 0
Neurodegenerative Disorders-Immunotherapy and Biomarkers
CONFERENCE 2009-05-28 00:00:00-2009-05-29 00:00:00 Rudbeck Laboratory, Uppsala, Sweden 28 May 2009 to 29 May 2009 Immunotherapy targeting abnormal protein aggregates has emerged as one of the most promising treatment strategies for neurodegenerative disorders. In a pioneer study, immunization against amyl
International Conference on Frontotemporal Dementias 2010
CONFERENCE 2010-10-06 00:00:00-2010-10-10 00:00:00 Indianapolis, Indiana, U.S.A. 06 October 2010 to 10 October 2010 The program is being designed to offer presentations of cutting-edge results relevant for research and clinical practice. In addition, there will be special sessions designed for family and
Eibsee Meeting on Cellular Mechanisms of Alzheimer’s Disease, 2008
CONFERENCE 2008-10-29 00:00:00-2008-11-01 00:00:00 Germany 29 October 2008 to 01 November 2008 0
2014 Zilkha Symposium on Alzheimer’s Disease and Related Disorders
CONFERENCE COVERAGE SERIES It’s Not All About You, Neurons. Glia, Blood, Arteries Shine at Symposium Fluid Markers and Imaging Back Idea of Breached Blood-Brain Barrier In Revival of Parabiosis, Young Blood Rejuvenates Aging Microglia, Cognition Glymphatic Flow, Sleep, microRNA Are
Three’s Company: Florbetaben Approved, Excludes AD Diagnosis
RESEARCH NEWS 2014-05-02 Research News A third amyloid imaging agent has joined the ranks of those approved for clinical use. Piramal Imaging’s PET tracer florbetaben, now rechristened Neuraceq, got the nod from the European Medicines Agency on February 20, and from the U.S. Food
Elizabeth Mormino on Emerging β-amyloid pathology and accelerated cortical atrophy.
COMMENT In this article, Mattson et al. examine gray-matter atrophy in clinically normal (CN) participants with 1) high and stable levels of CSF Aβ (s-Aβneg), 2) high and declining levels of CSF Aβ, and 3) low levels of CSF Aβ (ABpos). Although gray-matter differ
Kaj Blennow on Emerging β-amyloid pathology and accelerated cortical atrophy.
COMMENT This study is an excellent example of the importance of longitudinal biomarker studies in different stages of AD, from the preclinical to the dementia stage. Just as the map of the world was redrawn after the introduction of modern technology, knowledge a
Current Filters
No filters selected